Form 8-K - Current report:
SEC Accession No. 0001193125-25-153393
Filing Date
2025-07-01
Accepted
2025-07-01 06:09:24
Documents
12
Period of Report
2025-06-27
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d911089d8k.htm   iXBRL 8-K 26824
  Complete submission text file 0001193125-25-153393.txt   141195

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kura-20250627.xsd EX-101.SCH 2865
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kura-20250627_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kura-20250627_pre.xml EX-101.PRE 11271
14 EXTRACTED XBRL INSTANCE DOCUMENT d911089d8k_htm.xml XML 3639
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 251094090
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)